Proven invasive pulmonary aspergillosis

Microscopic analysis on sterile material: histopathologic, cytopathologic, or direct microscopic examination of a specimen obtained by needle aspiration or sterile biopsy in which hyphae are seen accompanied by evidence of associated tissue damage. Culture on sterile material: recovery of Aspergillus by culture of a specimen obtained by lung biopsy

Putative invasive pulmonary aspergillosis (all four criteria must be met)

1. Aspergillus-positive lower respiratory tract specimen culture OR positive Galactomannan antigen in BALF
2. Compatible signs and symptoms (one of the following)
   • Fever refractory to at least 3 d of appropriate antibiotic therapy
   • Recrudescent fever after a period of defervescence of at least 48 h while still on antibiotics and without other apparent cause
   • Pleuritic chest pain
   • Pleuritic rub
   • Dyspnea
   • Hemoptysis
   • Worsening respiratory insufficiency in spite of appropriate antibiotic therapy and ventilatory support
3. Abnormal medical imaging by portable chest X-ray or CT scan of the lungs
4. Either 4a or 4b
4a. Host risk factors (one of the following conditions)
   • Neutropenia (absolute neutrophil count 500/mm$^3$) preceding or at the time of ICU admission
   • Underlying hematological or oncological malignancy treated with cytotoxic agents
   • Glucocorticoid treatment (prednisone equivalent 20 mg/d)
   • Congenital or acquired immunodeficiency
4b. Semiquantitative Aspergillus-positive culture of BAL fluid without bacterial growth together with a positive cytological smear showing branching hyphae

Table S1. Modified AspICU criteria (after Blot et al., 2012)
Table S2: Classification in AspICU, EORTC and clinical decision to treat of critically ill patients with positive Aspergillus culture (PAC Group) and with only positive Galactomannan determination in BALF without growth of Aspergillus species in culture (OPG Group)

<table>
<thead>
<tr>
<th></th>
<th>All patients</th>
<th>PAC Group</th>
<th>OPG Group</th>
<th>p-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n= 85)</td>
<td>(n= 43)</td>
<td>(n= 42)</td>
<td></td>
</tr>
<tr>
<td><strong>AspICU</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proven IPA (%)</td>
<td>2 (2.4)</td>
<td>0 (0)</td>
<td>2 (4.8)</td>
<td>0.054</td>
</tr>
<tr>
<td>Putative IPA (%)</td>
<td>67 (78.8)</td>
<td>35 (81.4)</td>
<td>32 (76.2)</td>
<td></td>
</tr>
<tr>
<td>Colonization (%)</td>
<td>16 (18.8)</td>
<td>7 (16.3)</td>
<td>9 (21.4)</td>
<td></td>
</tr>
<tr>
<td><strong>EORTC (2008)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proven IPA (%)</td>
<td>2 (2.4)</td>
<td>0 (0)</td>
<td>2 (4.8)</td>
<td>0.634</td>
</tr>
<tr>
<td>Probable IPA (%)</td>
<td>16 (18.8)</td>
<td>9 (20.9)</td>
<td>7 (16.7)</td>
<td></td>
</tr>
<tr>
<td>Not classified (%)</td>
<td>67 (78.8)</td>
<td>33 (76.7)</td>
<td>34 (81)</td>
<td></td>
</tr>
<tr>
<td><strong>proposed revised EORTC/MSG criteria by Bassetti et al. (2015)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proven IPA (%)</td>
<td>2 (2.4)</td>
<td>0 (0)</td>
<td>2 (4.8)</td>
<td>0.032</td>
</tr>
<tr>
<td>Probable IPA (%)</td>
<td>54 (63.5)</td>
<td>33 (76.7)</td>
<td>21 (50.0)</td>
<td></td>
</tr>
<tr>
<td>Not classified (%)</td>
<td>29 (34.1)</td>
<td>10 (23.3)</td>
<td>19 (45.2)</td>
<td></td>
</tr>
<tr>
<td>Clinical decision to treat = clinical diagnosis IPA (%)</td>
<td>63 (74.1)</td>
<td>38 (88.4)</td>
<td>25 (59.5)</td>
<td>0.002</td>
</tr>
</tbody>
</table>

ASPICU Aspergillus in Intensive Care Units - Study Group, BALF bronchoalveolar lavage fluid, EORTC The European Organisation for Research and Treatment of Cancer, IPA invasive pulmonary aspergillosis
Data are presented as frequencies (percentage within subgroup) for qualitative variables, p-value calculated with Chi-Square test or Fisher's exact test as appropriate. * p-values are significant (p < 0.05).

*Modified for OPG Group with positive Galactomannan in the BALF (> 0.5) as entry criteria

Figure S1 Patients's disposition

positive clinical criteria (compatible signs and symptoms)

respiratory sampling as a part of clinical work-up

respiratory samples
  • positive for Aspergillus culture or
  • positive for Galactomannan test

n=91

informed consent

enrollment in prospective study

n=85

cHEST CT scan
bronchoalveolar lavage with
culture, antigen testing, PCR

serum Galactomannan testing

PAC group (n=43)  OPG group (n=42)

positive Aspergillus BAL culture  only positive BAL Galactomannan

antimycotic treatment by clinical decision

follow up
Figure S2 Box plot analysis of BALF Aspergillus Galactomannan titer (EIA) in patients with no growth of Aspergillus species in culture (OPG group) and patients with Aspergillus positive culture (PAC group)
Figure S3 Receiver operating curve analyses for Galactomannan test in BALF (titer EIA) by positive culture for Aspergillus species

AUC = 0.709